http://stage.rhythmtx.com/ http://stage.rhythmtx.com/news-resources/press-releases/rhythm-presents-cardiovascular-safety-data-from-phase-1b2a-clinical-trials-of-setmelanotide-in-obesity/ 2015-12-14T11:11:51+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-subsidiary-raises-40-million-in-oversubscribed-financing/ 2015-12-14T12:11:59+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-initiates-two-phase-2-clinical-trials-of-setmelanotide-rm-493-in-rare-genetic-disorders-of-obesity-caused-by-mc4-pathway-deficiencies/ 2015-12-14T12:14:54+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-appoints-fred-t-fiedorek-m-d-chief-medical-officer/ 2015-12-14T12:15:57+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-presents-clinical-data-that-rm-493-increases-energy-expenditure-in-obesity-study/ 2015-12-14T12:18:13+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-initiates-clinical-trial-of-rm-493-for-obesity-caused-by-genetic-variant/ 2015-12-14T12:20:04+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-initiates-phase-2-clinical-trial-of-rm-493-for-obesity/ 2015-12-14T12:22:07+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-names-lex-van-der-ploeg-chief-scientific-officer/ 2015-12-14T12:24:48+00:00 http://stage.rhythmtx.com/news-resources/press-releases/boston-november-30-2011-rhythm-announced-today-that-lex-van-der-ploeg-phd-has-joined-the-company-as-chief-scientific-officer-dr-van-der-ploeg-brings-to-rhythm-more-than-25-years-of-drug/ 2015-12-14T12:27:12+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-expands-scientific-advisory-board-for-clinical-programs-in-metabolic-diseases/ 2015-12-14T12:28:44+00:00 http://stage.rhythmtx.com/news-resources/press-releases/ipsen-grants-rhythm-exclusive-worldwide-license-for-two-programs-in-the-field-of-metabolic-disorders/ 2015-12-14T12:44:12+00:00 http://stage.rhythmtx.com/about-rhythm/company-overview/ 2015-12-15T11:06:21+00:00 http://stage.rhythmtx.com/pipeline/product-pipeline/ 2015-12-15T11:07:48+00:00 http://stage.rhythmtx.com/news-resources/press-releases/ 2015-12-15T11:08:20+00:00 http://stage.rhythmtx.com/contact/contact-rhythm/ 2015-12-15T11:08:45+00:00 http://stage.rhythmtx.com/about-rhythm/sitemap/ 2015-12-16T08:29:32+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-presents-positive-data-from-phase-1b-study-of-setmelanotide-for-the-treatment-of-genetic-obesity/ 2016-01-05T14:54:58+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-appoints-david-meeker-md-and-david-mcgirr-to-board-of-directors/ 2016-01-05T14:55:31+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-and-camurus-announce-license-agreement-for-extended-release-fluidcrystal-setmelanotide/ 2016-01-05T14:56:03+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-receives-orphan-drug-designation-for-setmelanotide-for-the-treatment-of-prader-willi-syndrome/ 2016-01-07T13:47:29+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-receives-fda-breakthrough-therapy-designation-for-setmelanotide-for-treatment-of-pomc-deficiency-obesity/ 2016-01-07T14:07:19+00:00 http://stage.rhythmtx.com/about-rhythm/investors/ 2016-01-12T17:36:23+00:00 http://stage.rhythmtx.com/wp-content/uploads/2015/12/Third-Rock.jpg http://stage.rhythmtx.com/wp-content/uploads/2015/12/pfizer.jpg http://stage.rhythmtx.com/wp-content/uploads/2015/12/nea.jpg http://stage.rhythmtx.com/wp-content/uploads/2015/12/mpm.jpg http://stage.rhythmtx.com/wp-content/uploads/2015/12/ipsen.jpg http://stage.rhythmtx.com/wp-content/uploads/2015/12/orbimed.jpg http://stage.rhythmtx.com/wp-content/uploads/2015/12/deerfield.jpg http://stage.rhythmtx.com/sitemap/ 2016-01-12T17:54:22+00:00 http://stage.rhythmtx.com/terms-of-use/ 2016-01-27T20:22:03+00:00 http://stage.rhythmtx.com/contact/contact-rhythm/ 2016-05-02T11:05:00+00:00 http://stage.rhythmtx.com/contact/directions/ 2016-05-02T11:09:41+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-announces-new-england-journal-of-medicine-publication-of-setmelanotide-phase-2-data-for-treatment-of-pomc-deficiency-obesity/ 2016-07-22T01:52:02+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-expands-series-b-financing-33-million-adds-pfizer-ventures-investor/ 2016-08-24T01:48:08+00:00 http://stage.rhythmtx.com/news-resources/press-releases/fda-office-of-orphan-products-development-awards-rhythm-1-million-grant-to-support-phase-2-study-of-setmelanotide-in-prader-willi-syndrome/ 2016-08-24T01:48:58+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-raises-25m-series-b-financing-diabetes-obesity-therapeutics/ 2016-08-24T01:52:10+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-closes-40-million-series-financing/ 2016-08-24T01:57:35+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-announces-21-million-series/ 2016-08-24T01:59:40+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-announces-the-genetic-obesity-project-to-expand-understanding-of-rare-genetic-disorders-of-obesity/ 2016-09-19T12:26:09+00:00 http://stage.rhythmtx.com/news-resources/press-releases/fiercebiotech-names-rhythm-fierce-15-biotechnology-company-2016/ 2016-09-19T13:00:05+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-presents-positive-initial-data-setmelanotide-lepr-deficiency-obesity/ 2016-11-04T12:35:58+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-announces-completion-of-41-million-mezzanine-financing/ 2017-02-16T13:26:04+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-starts-phase-3-clinical-trial-of-setmelanotide-for-rare-genetic-disorder-of-obesity/ 2017-05-04T11:59:34+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-appoints-head-of-sanofi-genzyme-dr-david-meeker-as-chairman-of-board-of-directors/ 2017-05-11T09:51:29+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-receives-expanded-fda-breakthrough-therapy-designation-for-setmelanotide-for-rare-genetic-disorders-of-obesity/ 2017-05-11T12:00:03+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-expands-phase-2-clinical-trials-of-setmelanotide-to-the-treatment-of-bardet-biedl-syndrome-obesity/ 2017-05-17T12:06:59+00:00 http://stage.rhythmtx.com/news-resources/in-the-news/ 2017-05-26T16:45:17+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-camurus-announce-positive-initial-data-extended-release-delivery-setmelanotide-treatment-rare-genetic-disorders-obesity/ 2017-08-01T11:46:04+00:00 http://stage.rhythmtx.com/news-resources/press-releases/rhythm-expands-executive-leadership-team/ 2017-08-01T11:59:53+00:00 http://stage.rhythmtx.com/careers/careers-at-rhythm/ 2017-10-04T17:12:35+00:00 http://stage.rhythmtx.com/about-rhythm/management/ 2017-10-04T17:14:42+00:00 http://stage.rhythmtx.com/about-rhythm/scientific-advisory-board/ 2017-10-04T17:15:42+00:00 http://stage.rhythmtx.com/about-rhythm/board-of-directors/ 2017-10-12T19:56:55+00:00 http://stage.rhythmtx.com/careers/careers-at-rhythm/ 2018-04-30T13:20:01+00:00 http://stage.rhythmtx.com/pipeline/rare-genetic-disorders-of-obesity/ 2018-05-01T23:52:06+00:00 http://stage.rhythmtx.com/wp-content/uploads/2018/04/Rhythm-Setmelanotide-Indications.jpg http://stage.rhythmtx.com/wp-content/uploads/2018/03/RhythmPrevalenceChart4.png http://stage.rhythmtx.com/pipeline/product-pipeline/ 2018-05-02T14:23:42+00:00 http://stage.rhythmtx.com/pipeline/published-research/ 2018-05-14T19:59:36+00:00 http://stage.rhythmtx.com/privacy-policy/ 2018-06-28T17:17:16+00:00 http://stage.rhythmtx.com/about-rhythm/company-overview/ 2018-08-16T14:45:01+00:00